Loading filters...
Publications per Year (4211 total)
17
1990
17
·
18
·
22
·
40
·
33
1995
39
·
61
·
46
·
62
·
69
2000
90
·
61
·
120
·
110
·
126
2005
125
·
118
·
128
·
143
·
121
2010
186
·
154
·
147
·
175
·
146
2015
201
·
192
·
179
·
184
·
163
2020
195
·
134
·
131
·
185
·
219
2025
54
·
Loaded
Click to load
50 / 4211 papers loaded(scroll for more)
202650 papers
GeneralAll Stages2026
Glucocorticoid Receptor Antagonist Approved for Ovarian Cancer.
Cancer Discov. 2026
GeneralEarly (I-II)2026
Influence of cardiophrenic lymph nodes on survival in patients receiving hyperthermic intraperitoneal chemotherapy for ovarian cancer in the OVHIPEC-1 trial.
Schreuder Goedheijt M et al. Gynecol Oncol. 2026
BRCA/HRDAdvanced (III-IV)2026
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.
Harter P et al. Ann Oncol. 2026
GeneralAll Stages2026
Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights.
Brodsky AL et al. Clin Cancer Res. 2026
GeneralAll Stages2026
Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery.
Guijarro-Campillo AR et al. Gynecol Oncol. 2026
GeneralEarly (I-II)2026
Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer.
Tewari S et al. Gynecol Oncol. 2026
GeneralEarly (I-II)2026
The role of hyperthermic intraperitoneal chemotherapy in newly diagnosed and recurrent ovarian cancer: A time-to-event meta-analysis of randomized trials.
Altayf A et al. Gynecol Oncol. 2026
GeneralEarly (I-II)2026
Minimally invasive surgery for advanced-stage ovarian cancer: a review of evidence and emerging paradigms.
Agusti N et al. Int J Gynecol Cancer. 2026
GeneralAll Stages2026
Circulating tumour cells are a prognostic indicator in advanced high-grade serous ovarian cancer and are associated with platelets and immune cells following dissemination.
Ward MP et al. Br J Cancer. 2026
GeneralAll Stages2026
Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines.
Peplinski RM et al. Gynecol Oncol. 2026
GeneralAll Stages2026
Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysis.
Kim JH et al. Int J Gynecol Cancer. 2026
GeneralEarly (I-II)2026
Real-world use and outcomes of hyperthermic intra-peritoneal chemotherapy for stage III ovarian cancer.
Lot Aronson S et al. Int J Gynecol Cancer. 2026
GeneralAll Stages2026
Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis.
Secchi M et al. Eur J Cancer. 2026
GeneralAdvanced (III-IV)2026
Multimodal prehabilitation improves functional capacity in patients with advanced ovarian cancer undergoing cytoreductive surgery.
Sebio-Garcia R et al. Int J Gynecol Cancer. 2026
GeneralEarly (I-II)2026
Frailty and body composition as predictors of postoperative outcomes in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy.
Hansen J et al. Gynecol Oncol. 2026
GeneralAll Stages2026
Trabectedin maintenance therapy after liposomal doxorubicin plus trabectedin combination in patients with relapsed ovarian cancer: the randomized, phase II TRAMANT study.
Scandurra G et al. Int J Gynecol Cancer. 2026
AntiangiogenicAll Stages2026
Maintenance therapy for platinum-sensitive recurrent ovarian cancer with a history of PARPi administration.
Asano F et al. J Gynecol Oncol. 2026
GeneralAdvanced (III-IV)2026
Feasibility of standard versus fractionated carboplatin-paclitaxel in older adults with ovarian cancer: a retrospective study.
Ashton E et al. Int J Gynecol Cancer. 2026
GeneralAll Stages2026
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).
Slomovitz BM et al. J Clin Oncol. 2026
ADC (FRα)All Stages2026
Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models.
Ettorre VM et al. Int J Gynecol Cancer. 2026
GeneralAdvanced (III-IV)2026
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.
Paracchini L et al. ESMO Open. 2026
GeneralAdvanced (III-IV)2026
Incidence of ESR1 gene mutations among patients with endometrioid endometrial cancer.
Jang M et al. Int J Gynecol Cancer. 2026
GeneralAll Stages2026
Elenagen, a p62/SQSTM1-encoding plasmid, improves overall survival in patients with platinum-resistant ovarian cancer: a phase II trial.
Krasny S et al. Int J Gynecol Cancer. 2026
GeneralAll Stages2026
Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial.
Hoogstad-van Evert JS et al. Gynecol Oncol. 2026
GeneralAdvanced (III-IV)2026
MRI in advanced ovarian cancer: multicentre MISSION trial.
Berardi E et al. Eur J Cancer. 2026
GeneralAdvanced (III-IV)2026
Survival benefit of platinum-based chemotherapy in non-surgically treated advanced ovarian cancer: A nationwide study.
Garkhail P et al. Gynecol Oncol. 2026
AntiangiogenicAll Stages2026
Intraoperative imaging of residual ovarian cancer after neoadjuvant chemotherapy using indocyanine green.
Achimas-Cadariu P et al. Int J Gynecol Cancer. 2026
GeneralAll Stages2026
Utility of CA125 KELIM in predicting benefit from hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer: pooled analysis of KGOG3042 and KOV-HIPEC-01.
Cho HW et al. Int J Gynecol Cancer. 2026
BRCA/HRDAll Stages2026
Clinical and biological characteristics associated with loss-of-heterozygosity in endometrial cancer.
Blanc-Durand F et al. J Gynecol Oncol. 2026
GeneralAll Stages2026
Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer.
Kwong FLA et al. Int J Gynecol Cancer. 2026
AntiangiogenicAll Stages2026
Maintenance of PARP Inhibitor Rechallenge Plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor.
Cho HW et al. Clin Cancer Res. 2026
BRCA/HRDAll Stages2026
Machine-learning survival models for predicting time to recurrence in epithelial ovarian cancer.
Nakayama J et al. Gynecol Oncol. 2026
BRCA/HRDAll Stages2026
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review.
Washington C et al. Gynecol Oncol. 2026
BRCA/HRDAdvanced (III-IV)2026
Impact of platinum-free interval and bevacizumab on second-line chemotherapy following progression on first-line PARP inhibitor maintenance in advanced ovarian cancer: A retrospective cohort study.
Hayakawa M et al. Gynecol Oncol. 2026
BRCA/HRDAll Stages2026
G-M6, an oleanane triterpenoid, represents a novel scaffold for PARP1 inhibition and anticancer activity.
Ding M et al. Gynecol Oncol. 2026
BRCA/HRDAdvanced (III-IV)2026
Efficacy and toxicity of PARP inhibitor in elderly patients with homologous recombination-deficient newly diagnosed advanced ovarian cancer: the role of dose modification.
Kim JH et al. J Gynecol Oncol. 2026
AntiangiogenicAll Stages2026
Gynecologic cancers in 2025: a year in review.
Arenhardt MP et al. Int J Gynecol Cancer. 2026
AntiangiogenicAdvanced (III-IV)2026
Surgical approach and maintenance therapy in advanced low-grade serous ovarian cancer: Insights from the French ESME database.
Papazyan T et al. Int J Gynecol Cancer. 2026
AntiangiogenicAll Stages2026
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.
Yuan G et al. Nat Cancer. 2026
AntiangiogenicAdvanced (III-IV)2026
Use of bevacizumab for patients with International Federation of Gynecology and Obstetrics stage IIIB to IV epithelial ovarian cancer undergoing primary debulking surgery and its association with oncologic outcomes: a Cancer Registry study.
Pfob A et al. Int J Gynecol Cancer. 2026
AntiangiogenicAll Stages2026
FUS-stabilized USP7 facilitates the bevacizumab resistance of ovarian cancer through deubiquitinating PTK2.
Wen X et al. J Gynecol Oncol. 2026
ADC (FRα)All Stages2026
Expression of antibody drug conjugate target antigens in ovarian sex cord stromal Tumors.
Brodsky AL et al. Gynecol Oncol. 2026
GeneralAdvanced (III-IV)2026
Survival in advanced-staged ovarian cancer treated without cytoreductive surgery-a systematic review and exploratory meta-analysis.
Garkhail P et al. Int J Gynecol Cancer. 2026
GeneralAll Stages2026
Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS).
Shahin MS et al. Gynecol Oncol. 2026
GeneralAll Stages2026
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.
Hollis RL et al. Clin Cancer Res. 2026
GeneralAdvanced (III-IV)2026
ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer.
González-Martín A et al. ESMO Open. 2026
BRCA/HRDAdvanced (III-IV)2026
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study.
Kristeleit RS et al. Ann Oncol. 2026
GeneralAll Stages2026
Gram-positive targeting antibiotics are associated with progression and death in women with platinum-sensitive recurrent high grade epithelial ovarian cancer.
Chambers LM et al. J Gynecol Oncol. 2026
GeneralAll Stages2026
First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.
Wang Y et al. Gynecol Oncol. 2026
BRCA/HRDAll Stages2026
A novel BRCA mutation classification system reveals differential responses to PARP inhibition and prognostic outcomes in epithelial ovarian cancer: a multicenter study.
Liu Q et al. ESMO Open. 2026